Liotta Heart (4)-to the latest version (SynCardia, both CE Mark and FDA approved), the TAMH is considered a relevant and effective intervention for patients with biventricular heart failure (5). However, as the field has matured, common complications of TAMH have been established, which include stroke, infection, bleeding, thrombosis, renal failure, and chronic anemia (6, 7) . Although the technology is advancing, hurdles still exist and provide a list of criteria that should be considered for any artificial heart. These include the need for continuous anti-coagulation, nonthrombogenicity, mechanical durability, an ability to reconcile the inter-dependency of left and right sides of the organ, and the need for a power source either externalized which limits the mobility and the quality of life of patients or incorporated as with a pacemaker (Fig. 1) .
Meanwhile, regenerative medicine's approaches to repairing or replacing damaged organs are maturing. Both scaffold technology and stem cell biology are now established regenerative medicine tools. Among scaffolds, various synthetic biomaterials have been studied as surrogates for the extracellular matrix (ECM), but none mimic the complexity and architecture of the native heart (8) . Decellularized ECM (dECM), in turn, has many characteristics of an optimal scaffold. It retains micro-and macro-architecture, contains biologically active molecules that modulate cell-cell and cell-ECM interactions and is vascularized allowing full thickness tissue generation (9, 10) . There is also dynamic reciprocity between the ECM and cells, which allows both to evolve as functional need changes, and makes it a unique scaffold.
An organ is comprised of cells, but cells are not the only component responsible for organ function. A complex organ such as the heart is composed of a tri-layered structure with regional specification where muscles, nerves, and blood vessels are integrated into an anatomical framework (i.e., scaffold) that provides both form and function for the cells (11) . It contains structural features (e.g., valves) that require intricately coordinated electrical and mechanical cues (12, 13) . It is also rich with growth factors and sugars that provide biological cues for cell behavior and contain a complex vascular network for supplementing nutrients to the cells. The ECM framework in the heart consists of both basement membrane and interstitium containing structural proteins such as collagens and laminins, as well as proteoglycans and polysaccharides that bind growth factors and other chemokines.
The first report of an engineered whole bioartificial heart was by our group in 2008, where we decellularized a cadaveric rat heart and then recellularized with neonatal rat cardiomyocytes (CMs) achieving approximately 25% of neonatal heart function (10) . In this study, the rat heart was decellularized using a perfusion-based technique which retained the 3-D ultrastructure with an intact vasculature. Furthermore, upon recellularizing, the neonatal CMs spatially organized and aligned with the dECM scaffolds (10) . Thereafter, integration of parenchymal, mural, stromal, and interstitial cells into the scaffold was required to simulate cardiac physiology (14) . In the same report, we demonstrated that a human-sized scaffold could be generated from decellularized porcine heart.
Porcine cardiac anatomy bears a striking resemblance (15) to that of humans, and because (glutaraldehyde-fixed) porcine valves are currently in human clinical use, researchers have primarily used pigs to obtain a dECM scaffold for use in human cardiac tissue engineering.
The goal of our group is to create a whole bioengineered heart built by using a decellularized scaffold for heart transplantation. We believe that harnessing the recipient's endogenous repair capabilities is a crucial step toward the full maturation of the new bioengineered transplanted organ. In supporting this strategy, we successfully performed heterotopic transplantation of decellularized whole porcine heart FIG. 1. A comparison between the design considerations for a total artificial mechanical heart and a bioartificial heart; insight into lessons learned.
scaffolds in acute porcine and chronic bovine animal models.
MATERIALS AND METHODS

Animals
All animal procedures and protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the Texas Heart Institute. The animals were handled and maintained in accordance with the requirements of the Laboratory Animal Welfare Act (P.L.89-544) and its 1970 (P.L. 91-579), 1976 (P.L. 94-279), and 1985 (P.L. 99-198) amendments. Compliance was accomplished by conforming to the standards in the Guide for the Care and the Use of Laboratory Animals, ILAR, National Academy Press, revised 2011. A preoperative screening was performed prior to surgery. Specific pathogen-free male or female pigs weighing 50-65 kg were used for heart harvesting to prepare decellularized matrices (n = 12). The pigs were housed for 7 weeks under appropriate living conditions before either heart harvesting or heterotopic heart transplantation. Euthanasia was performed using 30-150 mEq KCl under deep anesthesia following the AVMA Guidelines. After euthanasia, the hearts were harvested 7-10 days prior to each heterotopic procedure to have fresh decellularized scaffold and provide sufficient time for the complete decellularization procedure. Recipients of these hearts were either pigs in acute cases or, in chronic cases, specific pathogen-free male or female calves weighing 70-100 kg. Calves were housed in stalls upon arrival and throughout the quarantine period. Calves were stanchioned prior to surgery for surgical preparation and acclimation. During the post-operative recovery period, calves were housed in stanchions in the ICU for continuous observation due to numerous fluid and drug administrations and pressure monitoring. A total of nine acute and two chronic cases were performed.
Heart harvesting
Pigs were sedated via an intramuscular (IM) injection of telazol 4-6 mg/kg. Next, isoflurane was administered via facemask to induce general anesthesia for surgical interventions. Pigs were intubated and appropriately prepped for surgery. Intravenous (IV) catheters were established, and the animals were transported to the operating room. Appropriate preoperative analgesics such as buprenorphine HCL 0.005-0.1 mg/kg and/or flunixin meglumine 1.1-2.2 mg/kg IM, IV or SQ was administered.
Anesthesia was maintained with isoflurane and/or propofol IV (0.4 mg/kg/min for desired deep anesthesia effect). Anesthetic agents were given to ensure adequate levels of anesthesia were achieved without exposing the animal to unnecessary pharmacologic effects. Pancuronium bromide (0.04-0.1 mg/kg IV) or any other approved equivalent paralytic agent was administered prior to the start of the procedure to provide muscle relaxation.
Animals were appropriately prepped and draped to allow sterile, surgical access to the thoracic area. A median sternotomy was performed to expose the heart, and the pericardium between the ascending aorta and pulmonary artery and the area around the inferior and superior vena cava was dissected. 300 IU/Kg of nonfractionated heparin was administered, with the intent to totally heparinize the animal.
The ascending aorta was cannulated and clamped prior to infusion of heparinized saline, followed by infusion of cardioplegic solution. The superior vena cava, inferior vena cava, pulmonary vein and pulmonary artery were transected to evacuate blood and decompress the heart. The heart was extracted from the thoracic cavity and extensively washed with heparinized saline. After washing, the heart was weighed and put in a sterile biobag submerged in heparinized saline for transportation to the Regenerative Medicine Research Laboratory for ex vivo decellularization.
Decellularization of the porcine heart
Porcine hearts were decellularized as described in our previous study (16) . In brief, hearts were perfused in an inverted orientation with decellularization solutions at a constant 60 mm Hg pressure at the aortic root during our 3-day decellularization protocol: 4-h hypertonic (500 mM NaCl) solution, 2-h hypotonic (20 mM NaCl) solution, 56-h 1% SDS, 4-h 0.01% peracetic acid in 1% SDS and a final wash with 1X PBS.
Surgical technique for implantation of the scaffolds
Acute procedures-porcine recipients (n = 9) Scaffold preparation and anastomosis. Our initial goal of this acute experimental model was to create a closed coronary circuit in the heart scaffold with exclusive perfusion of the myocardial matrix by the coronary tree. For this purpose, the aortic valve was accessed by an aortotomy and leaflets were sutured together ( Fig. 2A) . This procedure diverted blood flow directly into the coronary circulation while avoiding overdistension of the nonworking left ventricle that would compress the capillary bed and medium-sized vessels and preclude adequate perfusion of the myocardium.
Several methods of heterotopic transplants were performed to find one that allowed adequate perfusion of the entire scaffold. In all procedures, the ascending aorta of the scaffold was directly anastomosed to the descending aorta of the recipient in an end-to-side fashion with a running suture of 5-0 polypropylene ( Fig. 3C and D) . Different methods of connecting the right side of the donor heart were employed: one was through closure of the donor heart tricuspid valve before connection ( Fig. 2B ) and anastomosis of a PTFE graft (8-10 mm) to the coronary sinus with a running suture of 5-0 polypropylene. Posteriorly, the PTFE graft was anastomosed to either right or left atria of the recipient hearts ( Fig.  3A and B). The second strategy used was to keep the tricuspid valve open and connect the pulmonary artery of the donor heart to the recipient pulmonary artery or right atrium with a graft. The superior vena cava, inferior vena cava, and pulmonary veins were closed in these cases.
Chronic procedures-bovine recipients (n = 2).
In the chronic bovine cases, the donor heart scaffolds did not undergo any anatomical intervention after completion of the decellularization process.
The animals were placed in right lateral decubitus and prepped with betadine solution from upper neck to hind quarters in the operating room. Following placement of sterile drapes, a left neck cut down was performed and external jugular vein and carotid artery were isolated and dissected for cardiopulmonary bypass. A left lateral thoracotomy was performed at the fourth rib which was removed. The internal thoracic artery was dissected, and a fluid-filled pressure line was inserted into the internal thoracic artery for monitoring of arterial pressure. The pericardium was opened to expose the heart. The lateral aspect of the proximal descending thoracic aorta and the main trunk of the pulmonary artery were partially dissected by applying a partial occlusion clamp. Heparin was then administered. Cannulas were next placed and secured in the left carotid artery and external jugular vein. Following initiation of the partial cardiopulmonary bypass and with the heart beating, a partial occlusion clamp was placed on the proximal descending thoracic aorta. The aorta of the decellularized heart was anastomosed in an end-to-side fashion to the recipient proximal descending thoracic aorta using 5-0 polypropylene suture. Following de-airing, the clamp was removed, the coronary arteries immediately began to fill with blood, and the color of the decellularized heart changed from ghostly white to pinkish red. A 16 mm Dacron graft was then anastomosed end-to-end fashion to the pulmonary artery of the decellularized heart using 5-0 suture. A partial occlusion clamp was placed on the recipient pulmonary artery, and the graft from the decellularized heart's pulmonary artery was anastomosed to the recipient pulmonary artery using 5-0 suture. Following de-airing, the clamps were removed. A left atrium-pulmonary artery anastomosis was undertaken to allow greater blood exchange and was accomplished using clamps and 5-0 suture. The heterotopic heart was then placed in a space above the aorta and below the dorsal spine. The arterial and venous cannulas were removed from the carotid artery and external jugular vein. The external jugular vein was ligated. A polyethylene pressure line was placed in the left carotid artery, secured and externalized. A 40 Fr. chest tube was placed in the left chest. Chest wires were used to approximate ribs, the chest incision closed in layers, and two On-Q infusion lines were placed along muscle line of the left chest. Estimated blood loss was less than 500 mL throughout the entire procedure.
Anticoagulation and angiography for acute and chronic cases
For anticoagulation, the calves received an IV infusion of heparin (25 000 units/250 mL D5W) at 1-5 mL/h. from post-operatory (POD) days 0-5. Coumadin (0-5 mg) was orally administered beginning on POD 4 based on the International Normalized Ratio result (keeping it between 2 and 2.5).
Coronary angiography was performed pre-and post-operatively on the decellularized heart scaffold in both acute cases and before euthanasia in chronic cases. All the donor decellularized scaffolds and recipient hearts were harvested after euthanasia for histopathological assessment.
Histology
After acute or chronic implantation, donor and recipient hearts were extensively rinsed with 1X PBS and then fixed in 10% neutral buffered formalin for 3 days. Hearts were subsequently grossed isolating left atrium (LA), right atrium (RA), left ventricle (LV), right ventricle (RV) and intraventricular septum (IVS). Samples were paraffin-embedded and 6μm thin sections were obtained. Sections were stained with hematoxylin & eosin (H&E) or Masson's trichrome.
Immunostaining
Immunohistochemistry was performed by using standard techniques that incorporate Tris-EDTA, pH 9 as the antigen retrieval buffer. Primary antibodies used were anti-CD31 (1:1500; Abcam, Cambridge, UK, ab10558), anti-α-smooth muscle actin (1:2000, Abcam, ab45694) and anti-β-MHC (1:5000; Abcam, ab11083). Secondary antibodies consisted of goat anti-rabbit (1:250; Bio-Rad, Hercules, CA, USA, 170-6515) or goat anti-mouse (1:100, Bio-Rad, 170-6516). Where light micrographs were imaged, DAB (Vector Laboratories, Burlingame, CA, USA) was used as a chromogen, where immunofluorescence was used, the secondary antibody used was goat anti-mouse 488 (1:200, Abcam, ab150117).
PCR
Pieces of approximately 12 mm 3 from left ventricle free wall from the donor and recipient pig hearts were harvested after termination of acute operative procedures and RNA was extracted using miRNeasy RNA extraction kit (Qiagen, Venlo, The Netherlands) according to manufacturer`s instructions. RNA was reverse transcribed using HighCapacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA), yielding a final concentration of 25 ng/µl of cDNA. PCR reactions were performed using 1.25ng of cDNA and Platinum Green Hot Start PCR Master Mix (2X) (ThermoFisher), according to manufacturer`s instructions. Primers for endothelial cells and myosin heavy chain were as follows: GAPDH_s 5′-CGTGTCGGTTGTGGATCTGA-3′; GAPDH_ as 5′-TGACGAAGTGGTCGTTGAGG-3′; VWF_s 5′-GTTTGCTGAGTGCCACAAGG-3′; VWF_as 5′-CAACTGCCTCACACACTTGC-3′, MYH7_s 5′-GAGACCCAGCGTTCTGTCAA-3′; MYH7_as 5′-GGGCGTTCTTTGCCTTAACC-3′.
RESULTS
Whole-heart decellularization
Porcine hearts were decellularized as previously reported (16) . After decellularization, the dECM had a low DNA (<9% cadaveric) and SDS content and an absence of cells but retained its three-dimensional myocardial architecture, both macroscopically and microscopically. Valves including chordae and vasculature were obvious features.
Acute heterotopic transplantation
This experiment was designed to test how soon a decellularized scaffold can recruit the recipient's cells when it is implanted in an intrathoracic location and connected to the recipient's circulation.
In our initial acute experiments, we noted macroscopically that distal coronary vessels were obstructed by air emboli after connecting the scaffold. This problem was managed by immediate pre-operative flushing of the decellularized heart scaffold with heparinized saline (1-unit heparin/1 mL saline) ante-and retrogradely under high pressure and using clinical grade cardioplegic infusion.
Blood flow was not physiologically normal in this model. The model was designed to determine if the decellularized heart scaffold could withstand a vascular connection for a few hours (4-6 h) evaluating perfusion and short-term patency of the coronary circulation, followed by histological analysis for cells present.
We performed nine acute porcine experiments with different anastomotic connections. In all cases, intrathoracic heterotopic transplantation of the decellularized scaffolds was successfully performed. No blood leakage from the decellularized heart surface or anastomosis was seen. Macroscopically, blood perfused through the coronary arteries, and their branch vessels retained their luminal diameter and shape (Fig. 4) . The scaffold integrity was sufficient to endure surgical procedures, and there was no stenosis at the anastomosis sites. Coronary artery angiography revealed patent coronary arteries after euthanization of the animal (4-6 h after de-clamping of the aorta) (Fig. 4C) in comparison with the scaffold before implantation (Fig. 4B) .
After 4-6 h of acute implantation, dECM donor hearts were evaluated. Histology revealed that the vascular system of the donor heart was preserved. Figure 5A shows the presence of blood cells from the recipient circulating through donor heart vessels. Endothelial cells from the recipient populated the dECM heart. Endothelial cells were present within vessels as evidenced by CD31 and von Willebrand factor (vWF) staining adjacent to lumen and appeared to be attached to the vessel wall (Fig. 5B,C,F) .
Chronic heterotopic transplantation
Taking advantage of the large animal experience of our group during the development of multiple circulatory assist devices, a well-established bovine model was selected for the chronic studies. Bovine physiology has been widely studied, the postoperative care is well understood, the large thoracic cavity favors the implantation of the new organ, and the trans-thoracic access to key anatomical structures without cracking the sternum. We successfully transplanted two heterotopic porcine decellularized heart scaffolds into two bovines. The calves were euthanized after 12 and 60 days, respectively. The calves functioned normally during this period and showed stable hemodynamic measurements, normal eating, and drinking.
Before euthanasia, hearts were catheterized and fluoroscopic images obtained. By 12 days, all vessels were occluded in the transplanted dECM donor heart. Following euthanasia, macroscopic and microscopic evaluation of the main cardiac structures were studied. At 12 days after implantation, the macroscopic study of the heart scaffold, as shown in Fig.  6A ,B, demonstrated the heart to be free of adhesions. However, adhesions were present at 60 days (Fig.  6C,D) .
After 60 days, the dECM heart was harvested, processed, and analyzed. Microscopic evaluation showed presence of complete vessels with both endothelial and smooth muscle cells (Fig. 7A-C) . Macroscopic evaluation showed adhesions with small blood vessels surrounding the heart scaffold. This likely was the source of the new vessels microscopically observed in the myocardial portion of the transplanted heart scaffold. Masson's trichrome and beta myosin heavy chain staining revealed the presence of what appeared to be nascent muscles (Fig. 7D,E) .
DISCUSSION AND CONCLUSIONS
The idea of building a heart to replace a failing one is not new. As early as the 1960s, when the heart was still viewed only as a pump, mechanical pumps were being designed to serve as replacements. Now fully 50 years later, even as knowledge about the physiology and function of the heart has evolved, the need to build an efficient, functional replacement still exists. In fact, as clinicians have prolonged the lives of patients suffering from acute myocardial infarction or chronic heart failure, the need for transplantable organs has dramatically increased. Today though, science and technology have advanced to the point that a bioartificial heart is the goal-a living organ manufactured for a patient and FDA-approved for transplant, available to meet the organ shortage.
Many of the lessons learned from, and tools used for, building a TAMH can be applied to engineering a bioartificial heart. Animal models for in vitro testing, organ design criteria, and functional requirementall have evolved from mechanical heart studies. For example, the development of circulatory support devices has occurred by using bovine models, leading to an understanding of the physiology and post-surgical care of these subjects. TAMH, even though successful, suffer from limitations such as large size, requirement for an external power source, lack of long-term durability, lack of biocompatibility, and necessity for lifetime anti-coagulation management. Bioengineered heart theoretically could meet these demands. We reasoned that bioengineering a heart could substantially benefit from the lessons learned from developing a TAMH and offer a biocompatible solution to the challenges associated with TAMH technologies (17) . An ideal tissue-engineered heart could have the capability of in vivo remodeling, regeneration, and growth. Furthermore, it would In this study, we tried to answer some of the questions or concerns faced by regenerative medicine scientists: (a) What will happen to the decellularized organ matrix in the absence of recellularization? (b) Will there be extensive fibrosis or remodeling? (c) Will there be significant recruitment of progenitor cells from the body to repopulate the organ "in vivo"?
Building a whole heart also requires delivering hundreds of billions of multiple types of cardiac cells appropriately and providing a milieu where they can survive, replicate, localize, and function. At present, these significant hurdles remain especially since the current survival limit for a healthy donor heart in vitro is approximately four hours.
To address these limitations, we employed a novel strategy of in vivo organ engineering, where decellularized porcine hearts were heterotopically transplanted with the intent to harness the inner capability of the body to repopulate the scaffold and help it mature. The heterotopic technique can be categorized into "working" and "nonworking" models. In nonworking models, the donor heart is perfused but does not support the recipient's circulation. Nonworking models have been applied in animal experiments in different anatomic positions (18) (19) (20) (21) (22) (23) (24) (25) for studying anastomotic techniques, immunosuppressive therapies, and graft rejection (26) . To our knowledge, this is the first study to address endogenous recruitment of endothelial precursor or endothelial cells into decellularized heart scaffolds transplanted in a large animal model. In a similar study, Kitahara et al. found that blood flow in the coronary arteries in decellularized hearts was short-lived due to thrombosis even after recellularization (27) . Furthermore, in their study, neither coronary perfusion nor muscular injection of mesenchymal stem cells prevented thrombosis. If a non-working heterotopic transplantation model is used without eliminating the ventricular chambers from the circulation, overdistension occurs, which increases coronary vascular resistance, prevents coronary flow, and leads to complete thrombosis of the coronary tree.
Although we were not able to detect patency of coronary circulation in the chronic cases, there was no evidence of scar formation in the scaffold after 60 days. Furthermore, new blood vessels and new muscle fibers were histologically detected, corresponding to fair vascularity of the graft. Most importantly, the decellularized matrix retained the underlying matrix of the vascular network, which could be readily connected to the circulation to facilitate rapid oxygen and nutrient delivery (28) . Similar to Kitahara et al., (27) we observed that the decellularized porcine heart scaffold could maintain surface integrity without any leaks despite high blood pressure, handling and surgical sutures, which are critical conditions for a transplantable organ. Kitahara et al (27) observed the abundant presence of inflammatory cells in the dECM after heterotopic heart transplantation (27), a condition that was not present in our acute transplants.
Coagulation dysfunction is a limiting factor for both whole-organ xenotransplantation and decellularized organ transplantation, as reported by several authors (27, (29) (30) (31) . Coagulation results in intense clotting, ischemic necrosis of tissues and consumptive coagulopathy in the recipient (32, 33) . An important step toward generating bioengineered transplantable matrices would be endothelization of the scaffolds prior to heterotopic transplantation to minimize coagulation dysfunction in the long term. Endothelial cells form the interface between tissues and blood and play an essential role in the control of vasoregulation and hemostasis. Upon vessel injury, activated endothelial progenitor cells (EPC) from peripheral blood and bone marrow migrate to the injury site, which contributes to neovascularization and wound healing (34) . Endothelial cells express vWF, a plasma glycoprotein that mediates platelet adhesion and aggregation to damaged vascular subendothelium and acts as a carrier for coagulation factor VIII in the circulation (35) . Given its essential role in hemostasis and the observation of blood clots in heterotopic transplants, it is not surprising to find this mRNA in the donor tissue after transplantation.
We observed an intense and rapid neo-endothelization of the decellularized matrix after heterotopic transplantation, as evidenced by CD31 positive staining on the surface of some vessels. CD31 expressing cells around vessels did not display the spindle-shaped nuclei characteristic of vascular endothelial cells, suggesting that these cells had migrated from the recipient bloodstream. The CD31 staining was also not detected in non-transplanted decellularized matrices. EPC migration may have reduced the surface area of exposed collagen in the decellularized matrix. Collagen is a protein abundant in ECM and is only exposed to the bloodstream when there is a vascular damage, acting as a substrate for platelet adhesion and activation (36) . Therefore, EPC migration with subsequent coating of collagen epitopes could reduce clot formation after transplantation of decellularized hearts.
Creating a bioartificial heart that can mimic the layered 3D organization and cell distribution of a solid organ has been challenging. Building a heart in vitro would require determining optimal human cell type for recellularizing, and homing them in the appropriate area in the heart matrix. This would require developing an optimal reseeding technique to achieve uniform cell distribution and retention for the vasculature and parenchyma (8) . Harnessing endogenous repair capability of the recipient thus solves some of the existing challenges and allows the host to provide cues for cell organization and distribution within the transplanted organ.
As reported by Kitahara et al. (27) , pre-endothelialization of the scaffold did not prevent clot formation in a non-working heterotopic transplantation model. To evaluate the pre-endothelialization of scaffolds, they should be implanted in a working heterotopic transplant model, where either the heart is already pumping or uses temporary circulatory support to prevent distention of the ventricles and allow proper coronary flow.
It has been shown that mechanical and electrical support play an important role in myocyte maturation when seeded in a scaffold (37) . Lovett et al. also showed that in vitro conditioning of cells, especially maturation of progenitor-type cells requires exposure to biophysical stimuli in a bioreactor setting to mimic the in vivo environment during development. For example, it is known that exposure of endothelial cells to shear stresses aligns them in the direction of the flow similar to its in vivo arrangement (38) . We truly advocate that dECM donor hearts should be partially recellularized in bioreactors where mechanical and electrical stimulation can be provided and be transplanted after at least a minimal level of maturation. For example, the use of pacemakers may be necessary when these organs are finally transplanted.
Challenges and future perspectives
The dream of an FDA-approved, transplantable, bioengineered heart depends on overcoming many hurdles including reliable, approvable matrix sources (e.g., porcine heart), the recellularization process (hundreds of billions of viable cells at an affordable cost, effective methods of recellularization), bioreactors, and organ potency (longevity, complexity, endogenous responsivity/repair, and physiologic response).
Inflammation and thrombosis are other challenges faced by cardiac tissue engineers. Residual DNA in the dECM scaffolds can generate an immune response. A major concern with anti-coagulants is excessive and uncontrollable hemorrhage, which is specially problematic for young patients. Complete endothelialization of blood-contact surfaces can minimize thrombosis and inflammatory response of engineered organs (8) .
The source of the organs for decellularization also remain an issue. Because porcine cardiac anatomy bears a striking resemblance (15) to that of humans, and because (fixed) porcine valves are currently in clinical use, researchers have primarily used pigs to obtain an ECM scaffold (15) for human cardiac tissue engineering.
Although this has helped to circumvent the ethical issues of using non-human primate organs, it raises other concerns that must be addressed-especially if the matrix to be used was not glutaraldehyde-fixed prior to use. Immunogenicity of the ECM and rejection due to the presence of the oligosaccharide galactose, α (1,3)-galactose (α-gal) epitope (39, 40) , the culprit xenoantigen, present on most glycosylated complexes throughout the matrix, is one pressing concern (41). Even though decellularization removes most cell-associated antigens, α-gal may remain within the scaffold. This could be at least partially circumvented by breeding pigs that lack the α-gal epitope, but an immunologically inert matrix has yet to be completely verified.
Results from non-working heterotopic models reported survival of porcine xenograft between 4 days to up to 3 months in a baboon model, while other studies demonstrated that heterotopically placed xenografts could support the circulation of the recipient (42) (43) (44) . Surprisingly, human organs for decellularization are widely available, because only the organs in near-pristine condition are used for transplantation. The number of donor organs that are unrecovered, for instance, those available as donor organs after cardiac death, is estimated to vastly exceed the demand for transplantation (45, 46) . However, adult human organs are often somewhat damaged, and their recovery comes along with a plethora of ethical questions. Still, it is fortunate that an alternate option exists. Determination of the best dECM source will be required before the bioengineered heart becomes a clinical reality (47) . In vivo graft viability should be the next challenge to be reached and function of mid-term (days to weeks) and long-term (months) in animal models, assessed via maintained structural integrity of the matrix, healthy remodeling by the body, viability of the cells, as well as other appropriate organ-specific functions.
To create functional grafts, the graft must be viable in vivo. More than two decades of efforts in tissue engineering indicate that this goal is not so easily achieved (48, 49) . The blood vessel ingrowth from the host may take up to several days to weeks to vascularize sufficiently and perfuse an acellular graft (50) . One of the advantages of the whole-organ decellularized scaffold is the intact and patent vascular bed, which if connected and vascularized, as performed in our experiment, could improve vascularity and enhance population of progenitor cells into the graft (in vivo recellularization).
New bioreactor systems to enhance ex vivo organ care at sterile and near-physiologic conditions are currently under investigation. They support perfusion, metabolism and overall vascular patency of an isolated donor heart prolonging the durability of the graft and maintaining its viability for a longer duration (51, 52) . We are designing experiments for partially recellularizing non-beating scaffolds that will use temporary mechanical circulatory support devices which are already approved to support the patient's failing heart in a similar clinical scenario, to promote constant drainage of blood from the ventricle chambers, thus preventing overdistension. The use of these clinically approved bioreactors could overcome an important hurdle in bioengineering hearts. As our group and others continue to work on these new paradigms, we will move closer to developing functional tissue engineering organs in the coming decade.
